8 completed, 6 unknown, 4 recruiting, 2 active not recruiting. 13 Phase 2, 8 Phase 3, 5 Phase 1, 1 Not applicable, 1 Phase 4.
Follow EC regimen: new trials by email Literature Review of EC regimen trials Research Report on EC regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib - Lung Cancer, Small Cell | Phase 2 | Recruiting | Shanghai Chest Hospital | 52 | 2024-10-13 | 2024-11-21 |
| Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Adebrelimab, Radiation Therapy, etoposide, carboplatin(EC) - Small Cell Lung Carcinoma | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 48 | 2024-02-10 | 2024-02-01 |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide - TNBC - Triple-Negative Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2023-04-08 | 2023-04-28 |
| To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) - Extensive Stage Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shanghai Henlius Biotech | 200 | 2022-11-18 | 2025-10-21 |
| Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study Epirubicin-cyclophosphamide, Paclitaxel - Breast Cancer | Completed | Institut de cancérologie Strasbourg Europe | 20 | 2021-11-04 | 2023-06-08 | |
| The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors Whole-ventricle irradiation, Carboplatin/etoposide, Ifosfamide/cisplatin/etoposide - Intracranial Germ Cell CNS Tumor, Childhood | Phase 2 | Recruiting | Beijing Tiantan Hospital | 150 | 2021-09-15 | 2021-11-18 |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients AL3810, carboplatin + etoposide, Placebo - Extensive-stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Haihe Biopharma Co., Ltd. | 313 | 2019-11-14 | 2020-02-05 |
| Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma Simmtecan, 5-FU and l-LV, Toripalimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder | Phase 2 / Phase 3 | Unknown | Peking University | 336 | 2019-06-19 | 2019-06-20 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide - Breast Cancer Stage II, Breast Cancer Stage III | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 366 | 2019-06-14 | 2026-05-12 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin - Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | AstraZeneca | 32 | 2016-04-28 | 2020-08-20 |
| Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma Carboplatin + etoposide, Thiotepa, Cyclophosphamide + Busilvex - High-risk Medulloblastoma | Phase 1 / Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 29 | 2013-09-14 | 2024-05-24 |
| Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627, EC regimen - Neutropenia, Breast Cancer | Phase 1 | Completed | EVIVE Biotechnology | 18 | 2012-12-01 | 2024-02-23 |
| Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer 5-FU（intravenous infusion）+epirubicin+cyclophosphamide, 5-FU（intravenous bolus）+epirubicin+cyclophosphamide, epirubicin+cyclophosphamide - Breast Cancer | Phase 4 | Completed | Tao OUYANG | 501 | 2010-10-01 | 2015-06-10 |
| A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients Epirubicin+Cyclophosphamide, liposomal-doxorubicin+Cyclophosphamide - Breast Cancer | Phase 2 | Unknown | TTY Biopharm | 254 | 2010-06-01 | 2021-11-23 |
| Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC) Endostar, Etoposide-Carboplatin - Small Cell Lung Cancer | Phase 2 | Completed | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd | 138 | 2009-05-01 | 2014-09-03 |
| Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel - Breast Cancer | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 400 | 2009-03-01 | 2016-02-10 |
| Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction Ultrasound, CNB, BCS, Modified Radical Mastectomy - Breast Cancer | Phase 3 | Unknown | Shandong Cancer Hospital and Institute | 4 | 2008-08-01 | 2013-08-06 |
| A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Obatoclax, Carboplatin/etoposide - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Gemin X | 218 | 2008-05-01 | 2016-07-21 |
Showing 20 of 23. Sign in to see all of them.
Breast Neoplasms (9) · Small Cell Lung Carcinoma (9) · Carcinoma, Neuroendocrine (2) · Lung Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Pancreatic Ductal (1) · Carcinoma, Small Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Neutropenia (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
GBG Forschungs GmbH (2) · AstraZeneca (1) · Beijing Tiantan Hospital (1) · Danish Oncological Lung Cancer Group (1) · EVIVE Biotechnology (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Gemin X (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Haihe Biopharma Co., Ltd. (1) · Henan Cancer Hospital (1) · Institut de cancérologie Strasbourg Europe (1) · King Faisal Specialist Hospital & Research Center (1) · Peking University (1) · Phanes Therapeutics (1) · Shandong Cancer Hospital and Institute (1)
China (9) · France (4) · Germany (4) · United States (4) · Poland (3) · Bulgaria (2) · Canada (2) · Czechia (2) · Hungary (2) · Italy (2) · Serbia (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1)
Adnan Ezzat, MD (1) · Christelle Dufour, MD (1) · Guangyuan Hu, Doctor (1) · Gunter von Minckwitz, MD, Prof. (1) · Gunter von Minckwitz, Prof. (1) · Hans Wildiers, MD, PhD (1) · Jean Viallet, MD (1) · Junliang Cai, MD (1) · Junning Cao, Professor (1) · Lin Shen (1) · Michael Untch, MD, Prof. (1) · Ming-Feng Hou, MD (1) · Qimig Wang, Doctor (1) · Seppo W Langer, MD PhD (1) · Shun Lu, Dr. (1)
PMID 22257523, PMID 22276820, PMID 24997137, PMID 25223482, PMID 29543566, PMID 29791287, PMID 34037241, PMID 37489066
2008 (1)